Enumeral Biomedical (ENUM) Expands Scientific Advisory Board To Support Development Of Novel Immunomodulators

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced the expansion of its Scientific Advisory Board (SAB) with the appointments of Giulio Draetta, M.D., Ph.D., and Kai Wucherpfennig, M.D., Ph.D., recognized leaders in the fields of tumor biology and cancer immunotherapy. Enumeral is applying its proprietary immune profiling technology to enable the development of potential best-in-class antibodies against targets in immuno-oncology and other disease applications. The Company's lead program is focused on a next-generation PD-1 antibody, which is expected to enter clinical testing in 2016.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.